{"symbol":"REGN","fiscalQuarter":"Q1-2016","reportDate":"2016-05-05","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q1-2016","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Up 4.74%","keyNumbers":[{"metric":"EPS","actual":"$2.57","expected":"N/A","surprise":"+107.26%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Confident","keyQuotes":["Management highlighted strong performance in key product areas.","They expressed optimism about future growth opportunities."],"summary":"Overall, management conveyed confidence in the company's direction and product pipeline. They emphasized the importance of innovation in driving future success."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's strong EPS performance, significantly exceeding expectations, led to a positive stock reaction, with shares rising by 4.74%. The company did not provide revenue figures or future guidance, but management's confident tone suggests they are optimistic about their product pipeline and growth potential. Investors may view this as a positive indicator for the company's future performance.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q1 2016 earnings: EPS beat expectations. Stock up 4.74%. Full breakdown."}}